Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

David A. Potter(Indiana University – Purdue University Indianapolis), Laura J. Esserman(University of California, San Francisco), Angela DeMichele(University of Pennsylvania), Denise M. Wolf, Richard B. Schwab(Center for Personalized Cancer Treatment), Alexandra Thomas(Cliniques Universitaires Saint-Luc), Laura van ‘t Veer, Erin Roesch(University of California San Diego), Amy Wilson(Quantum Leap Healthcare Collaborative), Judy C. Boughey(Mayo Clinic in Arizona), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Meghana V. Trivedi(University of Houston), Smita Asare(Quantum Leap Healthcare Collaborative), A. Jo Chien(University of California, San Francisco), Ruixiao Lu(Quantum Leap Healthcare Collaborative), Kathy S. Albain(Loyola University Chicago), Christina Yau(Hospital Authority), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Donald A. Berry(Berry & Associates (United States)), Debra Stafford(University of California, San Francisco), Hope S. Rugo(City of Hope), Dawn L. Hershman(Columbia University), Wen Li(University of California, San Francisco), Michelle Melisko(University of California, San Francisco), Susan Samson(University of California, San Francisco), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center)

Cancer Research

February 15, 2022

Cited by 0

|New England Journal of Medicine|2002|6.5k

|Immunity|2018|6.2k

|New England Journal of Medicine|2016|2.9k

|New England Journal of Medicine|2022|2.5k

|Annals of Oncology|2016|2.1k

Related Papers